Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis

Next Previous
X
Search
Trial Profile

A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 19 Jan 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Urinary incontinence
  • Focus Registrational; Therapeutic Use
  • Acronyms CONTENT1
  • Sponsors Ipsen

    • Most Recent Events

    • 01 Jan 2023 Results of a pooled analysis from two clinical studies: CONTENT1 and CONTENT2 assessing efficacy and safety of abobotulinumtoxinA according to etiology of neurogenic detrusor overactivity incontinence published in the Neurourology and Urodynamics
    • 01 Aug 2022 Results assessing the efficacy and safety of abobotulinumtoxinA (aboBoNT-A) for NDOI from two trials (CONTENT1, NCT02660138; CONTENT2, NCT02660359) assessing published in the European Urology
    • 09 Jun 2022 According to an Ipsen media release, result published in European Urology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top